Google Custom Search

Benefits of Screening for HCV Infection Based on Risk Factors

There is currently wide variation among healthcare providers with regard to screening patients for hepatitis C. While it is generally recommended that individuals with risk factors for infection should be screened, this is not always done in practice.

As reported in the January 2008 American Journal of Gastroenterology, C. Mallette from Brown University and colleagues looked at outcomes among individuals diagnosed through a screening program for veterans presenting for care at Veterans Administration (VA) healthcare facilities -- a group considered to be at high risk for HCV infection compared with the population as a whole.

Participants were assessed for HCV risk factors using a questionnaire. Those with an identified risk factor were offered HCV antibody testing. Between October 1998 and May 2004, a total of 25,701 patients were assessed, of whom 8471 had a risk factor for HCV.

Results

7.3% of veterans who had an identified risk factor tested positive for HCV antibodies.

Among the 260 individuals diagnosed through the screening program, 47% had chronic hepatitis C.

Among the patients with chronic HCV, 18% had evidence of advanced liver disease (stage 3-4 on biopsy or clinical cirrhosis).

34% had persistently normal alanine aminotransferase (ALT).

Two-thirds of patients who underwent liver biopsy had minimal or no fibrosis.

About half (47%) of the patients with chronic HCV detected through screening were candidates for treatment.

44% were not considered candidates for immediate treatment due to medical or psychiatric co-morbidities or active substance abuse.

8% of study participants died after a median follow-up period of 911 days.

Out of the 22 total deaths, 2 were liver-related.

Conclusion

Based on these findings, the authors concluded, "Screening for hepatitis C in persons at high risk can lead to early identification of individuals at risk for progressive liver disease who may benefit from antiviral therapy and counseling to reduce HCV-related liver injury."

3/07/08

Reference
C Mallette, MA Flynn, and K Promrat. Outcome of Screening for Hepatitis C Virus Infection Based on Risk Factors. American Journal of Gastroenterology 103(1): 131-137. January 2008.

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved
Combination Therapies
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin